Corporate Profile
To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Oct 14, 2021
Oct 11, 2021
Events
Sep 27, 2021 at 1:20 PM EDT
Jun 3, 2021 at 2:00 PM EDT